Regular tea drinkers—especially those who favor green tea over black—lived longer and developed CVD later than non-habitual tea drinkers in a recent study of more than 100,000 people in China.

Blood pressure-monitoring technology is hitting the wearables market hard this year, and tech companies are vying to create the optimal tool for tracking BP on the go. But one company thinks they already have it figured out, according to CNET—in the form of BP-monitoring earbuds.

Taking steps to keep older patients’ systolic blood pressure under the 120 mmHg mark could lower those patients’ risk of MI, stroke, death and mild cognitive impairment, according to a new study—but it could also fast-track a decline in kidney health.

Drugmaker AstraZeneca announced Jan. 6 that its SGLT2 inhibitor dapagliflozin, sold commercially as Farxiga, had been granted Priority Review by the FDA for patients with heart failure with reduced ejection fraction.

The Heart Rhythm Society and Consumer Technology Association will debut new consumer guidelines this week focused on wearables that detect and monitor cardiovascular metrics.

After a slow start, cardiac ERAS is gaining traction in some U.S. hospitals. Proponents explain how to overcome resistance. 

Research out of Norway suggests obesity, high blood pressure and diabetes could have a lot to do with CVD’s tendency to present later in life in women than in men.

A study published in JAMA Cardiology Jan. 2 suggests physicians may achieve comparable results when using either radial or femoral access for primary PCI in patients with STEMI.